Optimal management of endemic Burkitt lymphoma: a holistic approach mindful of limited resources

Figures & data

Table 1 Dose intensity of chemotherapeutic agents used in ten protocols of treatment for Burkitt lymphoma in Africa reported since 2000

Chemotherapy dose intensity (mg/m^2/week)
Study type	Citation (first author, year)	Cyclophosphamide	Prednisone	Vincristine	Methotrexate	Cytarabine	Doxorubicin	IT meds	Survival	Patients
Single	Kazembe,^Citation65 2003	600						No	43%	92
agent	Traore,^Citation66 2011	1,200						Yes	33%	178
	Hesseling,^Citation67 2009	600-1,200						Yes	48%	40
COMP	Koffi,^Citation68 2010	1,200			30	250		Yes	62%	85
	Ngoma,^Citation69 2012	600		0.7	37.5			Yes	62%	356
	Hesseling,^Citation70 2005	250	210	1	1,000			Yes	33%	42
	Hesseling,^Citation55 2003	250	210	1	1,000	200		Yes	59%	44
	Davidson,^Citation71 2010	300	75	0.75	75			Yes	72%	29
	Hesseling,^Citation72 2012	1,200		0.5	333			Yes	61%	129
	Traore,^Citation66 2011	500	100	0.67	1,000			Yes	50%	76
	Harif,^Citation73 2008	500	100	0.67	1,000			Yes	56%	187
		or			1,000	167
LMB	Harif,^Citation73 2008	500	100	0.67	1,000		20	Yes	75%	119
					1,000	167
		333	100	0.67			20
	Davidson,^Citation71 2006	500	100	0.75	1,000		20	Yes	81%	63
					1,000	167
		333	100	0.67			20

Note: Study types include single agent cyclophosphamide studies, studies using COMP⁵³ as the backbone of therapy, or those using variations the French LMB89⁵⁴ studies with doxorubicin. Doses displayed are for the agents used in the first 4 months of the protocols. The last three studies alternated cycles of chemotherapy, using two or three different combinations of chemotherapy. Use of intrathecal medications (IT) is indicated. Survival percentage as shown is based the number of patients enrolled in the final column. Survival time varied studies with doxorubicin. Survival time was reported at one to five years of follow-up.

Abbreviations: COMP, cyclophosphamide, vincristine, methotrexate, and prednisone; LMB, lymphoma malignancy B-cell; meds, medications.

Kazembe P, Hesseling PB, Griffin BE, Lampert I, Wessels G. Long term survival of children with Burkitt lymphoma in Malawi after cyclophosphamide monotherapy. Med Pediatr Oncol. 2003;40:23–25.

 PubMedGoogle Scholar

Traore F, Coze C, Atteby JJ, et al. Cyclophosphamide monotherapy in children with Burkitt lymphoma: a study from the French-African Pediatric Oncology Group (GFAOP). Pediatr Blood Cancer. 2011;56:70–76.

 PubMed Web of Science ®Google Scholar

Hesseling P, Molyneux E, Kamiza S, Israels T, Broadhead R. Endemic Burkitt lymphoma: a 28-day treatment schedule with cyclophosphamide and intrathecal methotrexate. Ann Trop Paediatr. 2009;29:29–34.

 PubMed Web of Science ®Google Scholar

Koffi GK, Tolo A, Nanho DC, et al. Results of treatment with CMA, a low intermediate regimen, in endemic Burkitt lymphomas in sub-Saharian Africa: experience of Cote d’Ivoire. International journal of hematology. 2010;91:838–843.

 Web of Science ®Google Scholar

Ngoma T, Adde M, Durosinmi M, et al. Treatment of Burkitt lymphoma in equatorial Africa using a simple three-drug combination followed by a salvage regimen for patients with persistent or recurrent disease. Br J Haematol. 2012;158:749–762.

 Web of Science ®Google Scholar

Hesseling P, Broadhead R, Mansvelt E, et al. The 2000 Burkitt lymphoma trial in Malawi. Pediatr Blood Cancer. 2005;44:245–250.

 PubMed Web of Science ®Google Scholar

Hesseling PB, Broadhead R, Molyneux E, et al. Malawi pilot study of Burkitt lymphoma treatment. Med Pediatr Oncol. 2003;41(6):532–540.

 Google Scholar

Davidson A, Desai F, Hendricks M, et al. The evolving management of Burkitt’s lymphoma at Red Cross Children’s Hospital. S Afr Med J. 2006;96:950–954.

 Web of Science ®Google Scholar

Hesseling P, McCormick P, Kouya F, et al. Burkitt lymphoma: residual abdominal tumor volume after induction therapy correlates with outcome. Pediatr Blood Cancer. 2010;55:761–762.

 PubMed Web of Science ®Google Scholar

Harif M, Barsaoui S, Benchekroun S, et al. Treatment of B-cell lymphoma with LMB modified protocols in Africa—report of the French-African Pediatric Oncology Group (GFAOP). Pediatr Blood Cancer. 2008;50:1138–1142.

 PubMed Web of Science ®Google Scholar

Anderson JR, Wilson JF, Jenkin DT, et al. Childhood non-Hodgkin’s lymphoma. The results of a randomized therapeutic trial comparing a four-drug regimen (COMP) with a ten-drug regimen (LSA2-L2). N Engl J Med. 1983;308(10):559–565.

 PubMed Web of Science ®Google Scholar

Patte C, Auperin A, Michon J, et al. The Societe Francaise d’Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;97(11):3370–3379.

 PubMed Web of Science ®Google Scholar